Celyad to Participate at Upcoming Healthcare Conferences

Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that management will participate at both the upcoming KBC Healthcare Conference and the Leerink Partners Roundtable Series: Rare Disease & Oncology.

The KBC Healthcare Conference will take place in New York, NY on September 27, 2018.The Leerink Partners Roundtable Series: Rare Disease & Oncology will take place in New York, NY on October 2-3, 2018 and the Company is scheduled to present on Thursday, October 3 at 4:00 p.m. ET.  A live webcast of the presentation can be accessed at http://wsw.com/webcast/leerink31/cyad/. An archived webcast recording will also be available under Events & Webcasts in the Investors section of the Company’s website.

Christian Homsy, CEO and Filippo Petti, CFO Celyad
Celyad Nicolas Van Hoecke, Director, Investor Relations & Communications
For Belgium : COMFI Sabine Leclercq
For France: Newcap Pierre Laurent and Nicolas Mérigeau
For the U.S.: LifeSci Investor Relations Daniel Ferry
About Celyad
About Celyad

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies. Celyad utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a single dose escalation Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma). Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the NASDAQ Global Market, all under the ticker symbol CYAD. 

Mont-Saint-Guibert (BELGIUM)
Axis Business Park
Rue Edouard Belin 2
1435 Mont-Saint-Guibert Belgium